Extraction, Characterization, and Biological Evaluation of Atranorin Against Diabetes-Induced Reproductive Dysfunction Through Modulation of Oxidative Stress, Inflammatory Pathways and Key Reproductive Enzymes

Atranorin, a lichen-derived compound, restored sperm motility by 189% and testosterone by 90% in alloxan-diabetic rats at 170 mg/kg.

Journal: International Journal of Molecular Sciences | Published: 2026-03-05 | Type: Journal Article (animal study) | PMID: 41828633 Authors: El-Sofany WI, Alshammari AF, Alshammari MZ, et al. (University of Ha'il, Saudi Arabia; Monastir University, Tunisia) Funding/COI: Funded by University of Ha'il. No conflicts of interest listed despite all but one author sharing the same institutional affiliation.

Summary

Atranorin (ATR) is a secondary metabolite extracted from lichens with known antioxidant and anti-inflammatory properties. This rat study tested whether ATR could reverse reproductive damage caused by alloxan-induced type 1 diabetes. Across a battery of sperm, hormonal, and enzymatic markers, diabetic rats treated with ATR at 170 mg/kg showed substantial recovery — but every result is in rodents, and the path from this to human fertility treatment is long and uncharted.

Claims

• ATR at 170 mg/kg bw reduced blood glucose by 66% in alloxan-diabetic male Wistar rats
• Sperm motility increased by 189%, sperm density by 87%, viability by 69%, and morphological abnormalities declined by 46%
• Testosterone recovered by approximately 90%, mediated through enhanced steroidogenic enzyme activity: 3β-HSD (+65%) and 17β-HSD (+102%)
• Oxidative stress markers improved substantially: total antioxidant status up 203%, TBARS down 73%, hydrogen peroxide down 45%, total oxidant status down 70%
• Seminal inflammation reduced: leukocyte infiltration down 51%, myeloperoxidase (MPO) activity down 68%
• Seminal plasma enzymes (HYAL +71%, ATPase +71%, PAP +79%) and fertility biomarkers (ADA +148%, LDH-C4 +62%) improved
• Trace minerals Zn²⁺ (+72%), Ca²⁺ (+96%), Mg²⁺ (+84%), and Se (+57%) were restored toward control levels
• Histology confirmed spermatogenesis and epididymal maturation were structurally restored

Study Quality

This is a preclinical rodent study. Alloxan injection is a well-established but blunt method of inducing type 1 diabetes in rats — it destroys pancreatic beta cells, which is broadly analogous to T1D but does not replicate the chronic complexity of human diabetic reproductive disease. The study measures an impressively broad panel of endpoints (enzymatic, hormonal, mineral, histological, sperm parameters), which is a strength for mechanistic insight, but the abstract does not report the number of animals per group, statistical methods, or variance data — serious omissions that make it impossible to assess confidence in the effect sizes.

All comparisons appear to be diabetic-untreated vs. diabetic-ATR-treated, with a non-diabetic control implied but not clearly described in the abstract. There is no positive control arm (e.g., insulin or an established antioxidant treatment), so it is unclear whether ATR is doing something specific or simply partially reversing diabetic hyperglycemia — since blood glucose fell 66%, much of the reproductive improvement may be a downstream consequence of glycemic control rather than a direct reproductive effect of ATR.

Red Flags

• Animal study only. All findings are in Wistar rats; no human pharmacokinetic, safety, or efficacy data exist for atranorin in reproductive contexts
• Sample size undisclosed in the abstract — effect sizes this large (189% motility increase) demand transparent N and variance reporting
• No positive control arm. Without a comparator (e.g., insulin, metformin, vitamin E), it is impossible to attribute effects specifically to ATR vs. general glycemic improvement
• Alloxan model limitations. Alloxan is cytotoxic and its T1D model is not well-suited to studying T2D-related infertility, which is the more clinically prevalent scenario
• COI not listed despite a single-institution authorship block — absence of a COI statement is not the same as absence of a conflict
• Dose translation is speculative. 170 mg/kg in rats does not straightforwardly convert to a human dose; allometric scaling and safety profiling are absent
• Atranorin has known cytotoxic and hepatotoxic properties in some studies — the paper does not appear to address safety or organ toxicity at the doses used

Strengths

• Broad, mechanistically coherent endpoint panel (hormonal, enzymatic, oxidative, mineral, histological) provides a plausible biological narrative for the observed effects
• Histological confirmation of spermatogenesis restoration is more rigorous than functional markers alone
• The antioxidant and anti-inflammatory mechanism is biologically plausible for diabetic reproductive pathology, which is genuinely oxidative-stress-driven
• Addresses a real clinical problem — diabetic male infertility is under-researched relative to its prevalence

Verdict

This paper generates a mechanistically coherent hypothesis — that atranorin's antioxidant and anti-inflammatory properties can partially reverse diabetic reproductive damage in rats — and does so with a reasonably thorough endpoint battery. But it cannot tell us whether ATR works in humans, at what dose, or whether it is safe. The missing animal counts and statistical details are a meaningful methodological gap. The spectacular effect sizes (189% sperm motility recovery) should trigger skepticism rather than excitement in the absence of variance data and a positive control arm. File this under "interesting rodent pharmacology" and wait for a toxicity study before anyone gets more excited.